Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen

NCT01720251 is registered in ClinicalTrials.gov with Anergis as lead sponsor.

NCT NCT01720251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01720251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen
Lead sponsor
Anergis
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
September 30, 2013
Enrollment
240 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis, rhinoconjunctivitis